Statistik Asas
| LEI | 549300T282D7Z2YESL90 |
| CIK | 886744 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Geron Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
Geron Corporation 2018 Inducement Award Plan, as amended EXHIBIT 10.3 Amended 2018 Inducement Award Plan GERON CORPORATION 2018 Inducement Award Plan Adopted by the Board of Directors: December 14, 2018 (with 3,000,000 share reserve) Amended and Restated: January 29, 2019 (added 5,000,000 shares) Amended and Restated: February 11, 2020 (added 1,300,000 shares) Amended and Restated: February 1, 2021 (added 800,000 shares) Amended and Restated: May 91, 20 |
|
| August 6, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Geron Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2018 Inducement Award Plan Common Stock, $0. |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
Geron Corporation Amended and Restated Severance Plan, as amended. EXHIBIT 10.2 Effective August 1, 2025 Geron Corporation Amended and Restated Severance Plan (and Summary Plan Description) This Geron Corporation Amended and Restated Severance Plan (the “Plan”) sets forth the severance benefits available to Covered Employees of Geron Corporation (together with any successor to substantially all of its business, stock or assets, the “Company”) whose employment is |
|
| August 6, 2025 |
Employment Agreement by and between the Company and Harout Semerjian, effective August 7, 2025. EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of August 7, 2025 (the “Effective Date”), by and between Harout Semerjian (“Executive”) and Geron Corporation, a Delaware corporation (the “Company”). Whereas, the Company desires to employ Executive to provide personal services to the Company and to provide Executive with certain compensation and benefi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON COR |
|
| August 6, 2025 |
Exhibit 99.1 Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights Seasoned Commercial Hematology and Oncology Leader Harout Semerjian Appointed as President and CEO Achieved $49.0 million in RYTELO® net product revenue in Q2 2025 Phase 3 IMpactMF clinical trial in relapsed/refractory myelofibrosis is over 95% enrolled and expected to be fully enrolled by y |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. |
|
| June 30, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Geron Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2018 Equity Incentive Plan Common Stock, $0. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 27, 2025 |
eron Corporation 2014 Employee Stock Purchase Plan, as amended Exhibit 10.2 Geron Corporation 2014 Employee Stock Purchase Plan Adopted by the Board of Directors: March 10, 2014 Approved by the Stockholders: May 20, 2014 Amended by the Board of Directors: February 16, 2022 Approved by the Stockholders: May 10, 2022 Amended by the Board of Directors: March 6, 2025 Approved by the Stockholders: May 21, 2025 1.General; Purpose. (a)This Plan provides a means by w |
|
| May 27, 2025 |
eron Corporation 2018 Equity Incentive Plan, as amended Exhibit 10.1 Geron Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: March 27, 2018 Approved by the Stockholders: May 15, 2018 Amended by the Board of Directors: February 12, 2020 Approved by the Stockholders: June 5, 2020 Amended by the Board of Directors: February 2, 2021 Approved by the Stockholders: May 11, 2021 Amended by the Board of Directors: February 16, 2022 Appro |
|
| May 7, 2025 |
by and between the Registrant and Dawn C. Bir, effective Exhibit 10.2 March 14, 2025 Dawn C. Bir Re: Employment Terms Dear Dawn: On behalf of Geron Corporation (“Geron” or the “Company”), I am pleased to extend you an offer of employment as Interim President and Chief Executive Officer commencing on March 17, 2025 (the “Start Date”), pursuant to the following terms. You will report to the Board of Directors (the “Board”). Your employment with the Compan |
|
| May 7, 2025 |
Exhibit 99.1 Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached a |
|
| May 7, 2025 |
Non-Employee Director Compensation Policy, as amended Exhibit 10.1 GERON CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ORIGINALLY ADOPTED BY THE BOARD OF DIRECTORS: MARCH 10, 2014 AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 12, 2015, MAY 6, 2015, FEBRUARY 11, 2016, JANUARY 31, 2018, MAY 15, 2018, OCTOBER 1, 2018, JANUARY 30, 2019, FEBRUARY 12, 2020, FEBRUARY 16, 2022, MARCH 7, 2022, FEBRUARY 14, 2024, MARCH 6, 2025 AND MAY 4, 2025 Each member |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CO |
|
| April 8, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 27, 2025 |
EXHIBIT 19.1 Geron Corporation Insider Trading Policy (Revised August 15, 2024) Table of Contents Introduction 1 Statement of Policy 2 Transactions Subject to this Policy 3 Persons Subject to this Policy 3 Material Nonpublic Information 3 Quarterly Trading Blackouts 4 Event-Specific Trading Blackouts 5 Exceptions to this Policy 5 Special and Prohibited Transactions 7 Pre-Clearance and Advance Noti |
|
| February 27, 2025 |
EXHIBIT 10.34 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. Revenue Participation Right Purchase and Sale Agreement By and Between Geron Corporation and Royalty |
|
| February 27, 2025 |
Employment Agreement by and between the Registrant and Joseph Eid, effective as of November 11, 2024 EXHIBIT 10.29 November 1, 2024 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of November 11, 2024 (the “Effective Date”), by and between Joseph Eid, M.D. (“Executive”) and Geron Corporation, a Delaware corporation (the “Company”). Whereas, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with ce |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPOR |
|
| February 27, 2025 |
Exhibit 10.33 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. LOAN AGREEMENT Dated as of November 1, 2024 among GERON CORPORATION (as Borrower and a Credit Part |
|
| February 27, 2025 |
Form of Restricted Stock Unit Agreement under 2018 Inducement Award Plan* EXHIBIT 10.17 Mandatory Sell to Cover Geron Corporation RSU Award Grant Notice (2018 Inducement Award Plan) Geron Corporation (the “Company”), pursuant to its 2018 Inducement Award Plan, as amended (the “Plan”), hereby awards to Participant (as defined below), the number of restricted stock units specified and on the terms set forth below (the “RSU Award”). The RSU Award is subject to all of the t |
|
| February 27, 2025 |
EXHIBIT 21.1 List of Subsidiaries Geron UK Limited, incorporated September 29, 2021 Geron Netherlands B.V., incorporated February 17, 2023 |
|
| February 27, 2025 |
2018 Inducement Award Plan, as amended January 1, 2025* EXHIBIT 10.13 Amended 2018 Inducement Award Plan Geron Corporation 2018 Inducement Award Plan Adopted by the Board of Directors: December 14, 2018 (with 3,000,000 share reserve) Amended and Restated: January 29, 2019 (added 5,000,000 shares) Amended and Restated: February 11, 2020 (added 1,300,000 shares) Amended and Restated: February 1, 2021 (added 800,000 shares) Amended and Restated: May 91, 2 |
|
| February 27, 2025 |
Form of Restricted Stock Unit Agreement under 2018 Equity Incentive Plan* EXHIBIT 10.12 Mandatory Sell to Cover Geron Corporation RSU Award Grant Notice (2018 Equity Incentive Plan) Geron Corporation (the “Company”), pursuant to its 2018 Equity Incentive Plan, as amended (the “Plan”) hereby awards to Participant (as defined below), the number of restricted stock units specified and on the terms set forth below (the “RSU Award”). The RSU Award is subject to all of the te |
|
| February 26, 2025 |
Exhibit 99.1 Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses ex |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 13, 2025 |
Corporate Presentation Our mission is to change lives by changing the course of blood cancer January 2025 Our mission is to change lives by changing the course of blood cancer Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025 As filed with the Securities and Exchange Commission on January 10, 2025 Registration No. |
|
| January 10, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Geron Corporation (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2018 Inducement Award Plan Common Stock, $0. |
|
| January 10, 2025 |
Geron Corporation 2018 Inducement Award Plan, as amended EXHIBIT 99.1 Amended 2018 Inducement Award Plan Geron Corporation 2018 Inducement Award Plan Adopted by the Board of Directors: December 14, 2018 (with 3,000,000 share reserve) Amended and Restated: January 29, 2019 (added 5,000,000 shares) Amended and Restated: February 11, 2020 (added 1,300,000 shares) Amended and Restated: February 1, 2021 (added 800,000 shares) Amended and Restated: May 91, 20 |
|
| November 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2427451d14ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi |
|
| November 14, 2024 |
GERN / Geron Corporation / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-gern093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* GERON CORPORATION (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 374163103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| November 14, 2024 |
GERN / Geron Corporation / RTW INVESTMENTS, LP Passive Investment SC 13G 1 p24-3251sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Geron Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 374163103 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to design |
|
| November 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-3251exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without |
|
| November 14, 2024 |
GERN / Geron Corporation / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d14sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* GERON CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 374163103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2024 |
Exhibit 99.2 Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors Geron received $250 million in gross proceeds at closing, with access to an additional $125 million in debt Strengthens balance sheet to support the commercial launch of RYTELO™ in the U.S. and potential launch in the EU, the ongoing Phase 3 IMpactMF trial in relapsed/refractory myelof |
|
| November 7, 2024 |
Exhibit 99.1 Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt FOSTER CITY, Calif |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERO |
|
| November 7, 2024 |
EXHIBIT 10.1 Geron Corporation 919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404 +1 650 473 7700 main +1 650 473 7750 fax www.geron.com EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of September 9, 2024 (the “Effective Date”), by and between James Ziegler (“Executive”) and Geron Corporation, a Delaware corporation (the “Company”). Whereas, the Company desi |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON COR |
|
| August 8, 2024 |
Exhibit 99.1 Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights U.S. commercial launch of RYTELO™ (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are relapsed/refractory to or ineligible for etythropoiesis-stimulating agents (ESAs), regardless of ring sideroblast (RS) status N |
|
| June 7, 2024 |
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia • Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast (RS) status • Durable and sustained red blood cell transfusion indepe |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CO |
|
| May 2, 2024 |
Exhibit 99.1 Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS FOSTER CITY, Calif., May 2, 2024 - Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomeras |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 27, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 20, 2024 |
Form of Pre-Funded Warrant to Purchase Common Stock Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GERON CORPORATION Warrant Shares: Date of Issuance: , 2024 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the con |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 20, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Geron Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Fees to be Paid Equity Common stock, par value $0. |
|
| March 20, 2024 |
Form of Pre-Funded Warrant to Purchase Common Stock Exhibit 1.1 Geron Corporation (a Delaware corporation) 41,999,998 shares of Common Stock Pre-Funded Warrants to Purchase up to 8,002,668 shares of Common Stock Underwriting Agreement March 19, 2024 Cowen and Company, LLC Stifel, Nicolaus & Company, Incorporated As representatives (the "Representatives") of the several Underwriters named in Schedule A hereto, c/o Cowen and Company, LLC 599 Lexingto |
|
| March 20, 2024 |
41,999,998 Shares of Common Stock Pre-Funded Warrants to Purchase 8,002,668 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-269111 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 4, 2023) 41,999,998 Shares of Common Stock Pre-Funded Warrants to Purchase 8,002,668 Shares of Common Stock We are offering 41,999,998 shares of our common stock, or for certain investors that so choose, in lieu of shares of common stock, pre-funded warrants to pu |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 19, 2024 |
March 2024 Enhancing the Lives of Patients with Hematologic Malignancies Corporate Presentation Exhibit 99. |
|
| March 19, 2024 |
Exhibit 99.1 Risk Factor Summary Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this summary to be a complete discussion of a |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 14, 2024 |
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS • FDA Oncologic Drugs Advisory Committee voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat based on results from the IMerge Phase 3 clinical trial • There are significant unmet needs across key TD LR-MDS patient populations, including difficult-to-treat subgroups that are underserved by currently available treatment options • June 16, 2024 PDUFA target action date for imetelstat NDA for the treatment of TD anemia in adult patients with LR-MDS FOSTER CITY, Calif. |
|
| February 28, 2024 |
Employment Agreement by and between the Registrant and Faye Feller, effective as of July 9, 2022* EXHIBIT 10.30 Geron Corporation 919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404 +1 650 473 7700 main +1 650 473 7750 fax www.geron.com EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of July 9, 2022 (the “Effective Date”), by and between Faye Feller (“Executive”) and Geron Corporation, a Delaware corporation (the “Company”) with corporate offices in Parsip |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 28, 2024 |
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS FOSTER CITY, Calif. |
|
| February 28, 2024 |
EXHIBIT 10.23 GERON CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ORIGINALLY ADOPTED BY THE BOARD OF DIRECTORS: MARCH 10, 2014 AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 12, 2015, MAY 6, 2015, FEBRUARY 11, 2016, JANUARY 31, 2018, MAY 15, 2018, OCTOBER 1, 2018, JANUARY 30, 2019, FEBRUARY 12, 2020, FEBRUARY 16, 2022, MARCH 7, 2022 AND FEBRUARY 14, 2024 Each member of the board of directors |
|
| February 28, 2024 |
EXHIBIT 4.1 DESCRIPTION OF CAPITAL STOCK References herein to “Geron,” “our,” “we,” “us” and the “Company” refer only to Geron Corporation. General Our restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 1,350,000,000 shares of common stock, par value $0.001 per share, and 3,000,000 shares of preferred stock, par value $0.001 per share. The follow |
|
| February 28, 2024 |
EXHIBIT 10.39 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) is the type that the registrant customarily and actually treats as private or confidential. THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT |
|
| February 28, 2024 |
EXHIBIT 21.1 List of Subsidiaries Geron UK Limited, incorporated September 29, 2021 Geron Netherlands B.V., incorporated February 17, 2023 |
|
| February 28, 2024 |
Incentive Compensation Recoupment Policy, effective October 2, 2023* EXHIBIT 97.1 Geron Corporation Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Geron Corporation, a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPOR |
|
| February 14, 2024 |
GERN / Geron Corporation / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-gern123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* GERON CORPORATION (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 374163103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm246065d10ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 14, 2024 |
GERN / Geron Corporation / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* GERON CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 374163103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2024 |
GERN / Geron Corporation / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Geron Corp Title of Class of Securities: Common Stock CUSIP Number: 374163103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 08, 2024 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| January 8, 2024 |
Company Logo Enhancing the Lives of Patients with Hematologic Malignancies Corporate Presentation January 2024 Forward-Looking Statements and Safe Harbor Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. |
|
| January 8, 2024 |
January 2024 Enhancing the Lives of Patients with Hematologic Malignancies Corporate Presentation2 Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 15, 2023 |
EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF GERON CORPORATION (as amended and restated effective December 14, 2023) Geron Corporation (the “Corporation”), pursuant to the provisions of Section 109 of the Delaware General Corporation Law (the “DGCL”), hereby adopts these Amended and Restated Bylaws (the “Bylaws”), which restate, amend and supersede the bylaws of the Corporation, as previously amende |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 26, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission F |
|
| November 2, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Geron Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Fees to be Paid Equity Common stock, par value $0. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERO |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| November 2, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-269111 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 4, 2023) $100,000,000 Common Stock We have entered into an At Market Issuance Sales Agreement, or sales agreement, dated as of November 1, 2023, with B. Riley Securities, Inc., or B. Riley Securities, relating to the shares of our common stock offered by this pros |
|
| November 2, 2023 |
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS Planning is ongoing for a potential commercial launch in the U. |
|
| November 2, 2023 |
GERON CORPORATION Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement November 1, 2023 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10107 Ladies and Gentlemen: Geron Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley Securities, Inc. (“B. Riley”), as follows: 1. Issuance and Sale of Shares. The |
|
| November 2, 2023 |
Geron Corporation 919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404 +1 650 473 7700 main +1 650 473 7750 fax www.geron.com EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of August 1, 2023 (the “Effective Date”), by and between Scott A. Samuels (“Executive”) and Geron Corporation, a Delaware corporation (the “Company”) Whereas, the Company desires to employ |
|
| November 2, 2023 |
Geron Corporation 919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404 +1 650 473 7700 main +1 650 473 7750 fax www.geron.com EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of September 25, 2023 (the “Effective Date”), by and between Michelle Robertson (“Executive”) and Geron Corporation, a Delaware corporation (the “Company”) Whereas, the Company desires to e |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 3, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Geron Corporation (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2018 Equity Incentive Plan Common Stock, $0. |
|
| August 3, 2023 |
EXHIBIT 99.1 Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results Submitted U.S. New Drug Application in lower risk MDS in June 2023 Additional data and analyses from IMerge Phase 3 presented at medical meetings further strengthen value proposition and differentiation of imetelstat Potential U.S. commercial launch in lower risk MDS expected in first half of 2024 |
|
| August 3, 2023 |
As filed with the Securities and Exchange Commission on August 3, 2023 As filed with the Securities and Exchange Commission on August 3, 2023 Registration No. |
|
| August 3, 2023 |
2018 Inducement Plan, as amended. Geron Corporation 2018 Inducement Award Plan Adopted by the Board of Directors: December 14, 2018 (with 3,000,000 share reserve) Amended and Restated: January 29, 2019 (added 5,000,000 shares) Amended and Restated: February 11, 2020 (added 1,300,000 shares) Amended and Restated: February 1, 2021 (added 800,000 shares) Amended and Restated: May 91, 2021 (added 5,000,000 shares) Amended and Restated: February 2, 2022 (added 1,000,000 shares) Amended and Restated: July 15, 2022 (added 5,000,000 shares) Amended and Restated: June 16, 2023 (added 13,900,000 shares) 1. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON COR |
|
| June 2, 2023 |
2018 Equity Incentive Plan, as amended Exhibit 10.1 Geron Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: March 27, 2018 Approved by the Stockholders: May 15, 2018 Amended by the Board of Directors: February 12, 2020 Approved by the Stockholders: June 5, 2020 Amended by the Board of Directors: February 2, 2021 Approved by the Stockholders: May 11, 2021 Amended by the Board of Directors: February 16, 2022 Appro |
|
| June 2, 2023 |
Certificate of Amendment of the Restated Certificate of Incorporation EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF GERON CORPORATION, a Delaware corporation The undersigned, Stephen Rosenfield, hereby certifies that: FIRST. He is the duly elected and acting Executive Vice President, Chief Legal Officer and Corporate Secretary of Geron Corporation, a Delaware corporation (the “Corporation”). SECOND. The Corporation’s Restated C |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CO |
|
| May 11, 2023 |
EXHIBIT 99.1 Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights Planned submission of U.S. New Drug Application on track for June 2023 Additional data and analyses from IMerge Phase 3 expected to be presented at upcoming medical meetings further strengthen differentiating qualities of imetelstat Preparations for potential commercial launch in the U.S. ongoing FO |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 20, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 20, 2023 |
22nd Annual Needham Virtual Healthcare Conference Slides EXHIBIT 99.1 22nd Annual Needham Virtual Healthcare Conference Slides |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 17, 2023 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE EXHIBIT 99.2 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE GERON CORPORATION STOCKHOLDER DERIVATIVE LITIGATION ) ) Consolidated C.A. No. 2020-0684-SG NOTICE OF PENDENCY OF SETTLEMENT OF DERIVATIVE LITIGATION TO: ALL CURRENT OR OTHERWISE APPLICABLE STOCKHOLDERS OF GERON CORPORATION (NASDAQ SYMBOL: GERN) PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS WILL BE AFFECTED BY |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 17, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 16, 2023 |
EXHIBIT 99.1 Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones Positive Phase 3 Top-Line Results in Lower Risk MDS Reported in January 2023 Planned 2023 Regulatory Submissions in the U.S. and EU On Track Preparations for Potential Commercial Launch in U.S. Ongoing FOSTER CITY, Calif., March 16, 2023 - Geron Corporation (Nasdaq: GERN), a late-stag |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 16, 2023 |
EXHIBIT 21.1 List of Subsidiaries Geron UK Limited, incorporated September 29, 2021 Geron Netherlands B.V., incorporated February 17, 2023 |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPOR |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Geron Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 374163103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2023 |
GERN / Geron Corporation / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* GERON CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 374163103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 3, 2023 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Geron Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 374163103 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (N |
|
| January 13, 2023 |
GERN / Geron Corporation / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-gern010623.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GERON CORPORATION (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 374163103 (CUSIP Number) January 06, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 6, 2023 |
55,876,297 Shares of Common Stock Pre-Funded Warrants to Purchase 25,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269111 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 4, 2023) 55,876,297 Shares of Common Stock Pre-Funded Warrants to Purchase 25,000,000 Shares of Common Stock We are offering 55,876,297 shares of our common stock, or for certain investors that so choose, in lieu of shares of common stock, pre-funded warrants to purchase 25,000,000 share |
|
| January 6, 2023 |
Form of Pre-Funded Warrant to Purchase Common Stock EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GERON CORPORATION Warrant Shares: Date of Issuance: , 2023 (such date, the ?Issue Date?) Warrant No.: PF-[ ] THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, the registered holder hereof or its permitted assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the con |
|
| January 6, 2023 |
Youâve Exceeded the SECâs Traffic Limit Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Geron Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Fees to be Paid Equity Common stock, par value $0. |
|
| January 6, 2023 |
EXHIBIT 1.1 Geron Corporation (a Delaware corporation) 55,876,297 shares of Common Stock Pre-Funded Warrants to Purchase up to 25,000,000 shares of Common Stock Underwriting Agreement January 5, 2023 Goldman Sachs & Co. LLC As representative (the "Representative") of the several Underwriters named in Schedule A hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Ladies and |
|
| January 6, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 5, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| January 5, 2023 |
$175,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated January 5, 2023 Relating to Preliminary Prospectus Supplement, dated January 4, 2023 Registration Statement No. |
|
| January 4, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate EX-4.8 EXHIBIT 4.8 GERON CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF 1 GERON CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “ Agreement ”), dated as of [•], between GERON CORPORATION , a Delaware corporation (the “ Company ”) and [•], a [corporation] [national banking association]organized and existing |
|
| January 4, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate EX-4.7 EXHIBIT 4.7 GERON CORPORATION AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF GERON CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between GERON CORPORATION, a Delaware corporation (the “Company ”), and [•], a [corporation] [national banking association] organized and existing und |
|
| January 4, 2023 |
Subject to Completion, dated January 4, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-269111 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Subject to Completion |
|
| January 4, 2023 |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS EX-99.1 2 gern-ex991.htm UPDATED COMPANY DISCLOSURE EXHIBIT 99.1 Unless the context indicates otherwise, the terms “we,” “us” and “our” refer to Geron Corporation, a Delaware corporation, and its subsidiary on a consolidated basis. This Exhibit 99.1 includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Exhi |
|
| January 4, 2023 |
As filed with the Securities and Exchange Commission on January 4, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 4, 2023 Registration No. |
|
| January 4, 2023 |
Form of Indenture between Geron Corporation and a trustee to be named EX-4.5 EXHIBIT 4.5 GERON CORPORATION Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sec |
|
| January 4, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate EX-4.6 EXHIBIT 4.6 GERON CORPORATION AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF 1 GERON CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “ Agreement ”), dated as of [•], between GERON CORPORATION , a Delaware corporation (the “ Company ”), and [•], a [corporation] [national banking association] organized and existing under |
|
| January 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 4, 2023 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| January 4, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Geron Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0. |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 22, 2022 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE EXHIBIT 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE GERON CORPORATION STOCKHOLDER DERIVATIVE LITIGATION ) ) Consolidated C.A. No. 2020-0684-SG STIPULATION OF SETTLEMENT This Stipulation of Settlement (“Stipulation”) is made and entered into as of December 21, 2022, between and among, (a)(i) plaintiffs in the above-captioned consolidated derivative action (the “Action”), (ii) plain |
|
| November 7, 2022 |
Form of 2018 Equity Incentive Plan Option Agreement (Performance Based)* EXHIBIT 10.3 Geron Corporation 2018 Equity Incentive Plan Performance Vesting Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) Pursuant to your Stock Option Grant Notice (?Grant Notice?) and this Option Agreement (the definition of which shall include, if you are resident or working outside the U.S., the general non-US terms and any special terms and conditions for your count |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERO |
|
| November 7, 2022 |
Form of 2018 Inducement Award Plan Option Agreement (Performance Based)* EXHIBIT 10.7 Geron Corporation 2018 Inducement Award Plan Performance Vesting Option Agreement (Nonstatutory Stock Option) Pursuant to your Stock Option Grant Notice (?Grant Notice?) and this Option Agreement (the definition of which shall include, if you are resident or working outside the U.S., the general non-US terms and any special terms and conditions for your country, each set out in the at |
|
| November 7, 2022 |
Form of 2018 Equity Incentive Plan Option Agreement (Time Based)* EXHIBIT 10.2 Geron Corporation 2018 Equity Incentive Plan Time Vesting Option Agreement (Incentive Stock Option Or Nonstatutory Stock Option) Pursuant to your Stock Option Grant Notice (?Grant Notice?) and this Option Agreement (the definition of which shall include, if you are resident or working outside the U.S., the general non-US terms and any special terms and conditions for your country, eac |
|
| November 7, 2022 |
Form of 2018 Inducement Award Plan Option Agreement (Time Based)* EXHIBIT 10.6 Geron Corporation 2018 Inducement Award Plan time vesting Option Agreement (Nonstatutory Stock Option) Pursuant to your Stock Option Grant Notice (?Grant Notice?) and this Option Agreement (the definition of which shall include, if you are resident or working outside the U.S., the general non-US terms and any special terms and conditions for your country, each set out in the attached |
|
| November 7, 2022 |
UK Sub-Plan to 2018 Equity Incentive Plan* EXHIBIT 10.1 UK SUB-PLAN TO THE GERON CORPORATION 2018 EQUITY INCENTIVE PLAN This sub-plan (the "UK Sub-Plan") to the Geron Corporation 2018 Equity Incentive Plan (the ?Plan?) governs the grant of Stock Awards to United Kingdom Employees, and has been adopted in accordance with Section 2(b)(x) of the Plan. The UK Sub-Plan incorporates all the provisions of the Plan except as modified in accordance |
|
| November 7, 2022 |
UK Sub-Plan to 2018 Inducement Award Plan* EXHIBIT 10.5 UK SUB-PLAN TO THE GERON CORPORATION 2018 INDUCEMENT AWARD PLAN This sub-plan (the "UK Sub-Plan") to the Geron Corporation 2018 Inducement Award Plan (the ?Plan?) governs the grant of Stock Awards to United Kingdom Employees, and has been adopted in accordance with Section 2(b)(x) of the Plan. The UK Sub-Plan incorporates all the provisions of the Plan except as modified in accordance |
|
| November 3, 2022 |
Exhibit 99.1 Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected to Support Planned Milestones and Operations Through Middle of 2024 Conference Call Scheduled for 9:00 a.m. ET Today FOSTER CITY, Cal |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 7, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 6, 2022 |
Stipulation and Agreement of Settlement, dated September 2, 2022 EXHIBIT 99.1 Stipulation and Agreement of Settlement, dated September 2, 2022 KAPLAN FOX & KILSHEIMER LLP Laurence D. King (SBN 206423) Kathleen A. Herkenhoff (SBN 168562) Blair E. Reed (SBN 316791) 1999 Harrison Street, Suite 1560 Oakland, CA 94612 Telephone: (415) 772-4700 Facsimile: (415) 772-4707 [email protected] [email protected] [email protected] KAPLAN FOX & KILSHEIMER LLP Robe |
|
| September 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 2, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 11, 2022 |
2018 Inducement Award Plan, as amended July 15, 2022* EXHIBIT 10.3 Geron Corporation 2018 Inducement Award Plan Adopted by the Board of Directors: December 14, 2018 (with 3,000,000 share reserve) Amended and Restated: January 29, 2019 (added 5,000,000 shares) Amended and Restated: February 11, 2020 (added 1,300,000 shares) Amended and Restated: February 1, 2021 (added 800,000 shares) Amended and Restated: May 91, 2021 (added 5,000,000 shares) Amended |
|
| August 11, 2022 |
EXHIBIT 10.4 Certain portions of this exhibit (indicated by asterisks) have been omitted as the Registrant has determined that the information is both not material and is the type that the Registrant treats as private or confidential SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of June 30, 2022 (the ?Amendment Eff |
|
| August 11, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Geron Corporation (Exact name of Registrant as Specified in its Charter) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0. |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON COR |
|
| August 11, 2022 |
EXHIBIT 99.1 Press Release Dated, August 11, 2022 Geron Corporation Reports Second Quarter 2022 Financial Results Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected to Support Planned Milestones and Operations Through Middle of 2024 Conference Call Scheduled for 4:30 p.m. ET Today FOSTER CITY |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2022 |
2014 Employee Stock Purchase Plan, as amended* EXHIBIT 10.2 Geron Corporation 2014 Employee Stock Purchase Plan Adopted by the Board of Directors: March 10, 2014 Approved by the Stockholders: May 20, 2014 Amended by the Board of Directors: February 16, 2022 Approved by the Stockholders: May 10, 2022 1. General; Purpose. (a) This Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2022 |
2018 Equity Incentive Plan, as amended* EXHIBIT 10.1 Geron Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: March 27, 2018 Approved by the Stockholders: May 15, 2018 Amended by the Board of Directors: February 12, 2020 Approved by the Stockholders: June 5, 2020 Amended by the Board of Directors: February 2, 2021 Approved by the Stockholders: May 11, 2021 Amended by the Board of Directors: February 16, 2022 Appro |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of (Commission File Number) (IRS Employ |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CO |
|
| May 9, 2022 |
EXHIBIT 99.1 Press Release Dated May 9, 2022 Geron Corporation Reports First Quarter 2022 Financial Results Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Started the Phase 1 IMproveMF Study in Frontline MF in May 2022 Current and Projected Financial Resources Expected to be Sufficient to Reach Planned Milestones through Year-End 2023 Con |
|
| April 13, 2022 |
21st Annual Needham Virtual Healthcare Conference presentation slides. |
|
| April 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 13, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-20859 (Commission File Number) 75-2 |
|
| April 8, 2022 |
GERN / Geron Corporation / Vivo Opportunity, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Geron Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 374163103 (CUSIP Number) April 1, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| March 30, 2022 |
Form of Warrant to Purchase Common Stock EXHIBIT 4.2 COMMON STOCK PURCHASE WARRANT CUSIP 374163 137 GERON CORPORATION Warrant Shares: Date of Issuance: , 2022 (such date, the ?Issue Date?) THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, the registered holder hereof or its permitted assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions set fo |
|
| March 30, 2022 |
Form of Pre-Funded Warrant to Purchase Common Stock EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GERON CORPORATION Warrant Shares: Date of Issuance: , 2022 (such date, the ?Issue Date?) Warrant No.: PF-[ ] THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, the registered holder hereof or its permitted assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the con |
|
| March 30, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-248637 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 6, 2020) 53,333,334 Shares of Common Stock Pre-Funded Warrants to Purchase 18,095,238 Shares of Common Stock Warrants to Purchase 35,714,286 Shares of Common Stock We are offering (i) 53,333,334 shares of our common stock, pre-funded warrants to purchase 18,095,238 shares of our common |
|
| March 30, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 29, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 30, 2022 |
EXHIBIT 1.1 Execution Version GERON CORPORATION (a Delaware corporation) 53,333,334 Shares of Common Stock Pre-Funded Warrants to Purchase up to 18,095,238 Shares of Common Stock Common Warrants to Purchase up to 35,714,286 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 29, 2022 GERON CORPORATION (a Delaware corporation) 53,333,334 Shares of Common Stock Pre-Funded Warrants to Purchase |
|
| March 29, 2022 |
Subject to Completion, dated March 29, 2022 Filed Pursuant to Rule 424(b)(5) Registration No. 333-248637 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Subject to Completion |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 10, 2022 |
Amended and Restated Severance Plan, effective as of January 1, 2022* EXHIBIT 10.22 Effective January 1, 2022 Geron Corporation Amended and Restated Severance Plan (and Summary Plan Description) This Geron Corporation Amended and Restated Severance Plan (the ?Plan?) sets forth the severance benefits available to Covered Employees of Geron Corporation (together with any successor to substantially all of its business, stock or assets, the ?Company?) whose employment i |
|
| March 10, 2022 |
Non-Employee Director Compensation Policy, as amended February 16, 2022 and March 7, 2022* EXHIBIT 10.20 GERON CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ORIGINALLY ADOPTED BY THE BOARD OF DIRECTORS: MARCH 10, 2014 AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 12, 2015, MAY 6, 2015, FEBRUARY 11, 2016, JANUARY 31, 2018, MAY 15, 2018, OCTOBER 1, 2018, JANUARY 30, 2019, FEBRUARY 12, 2020, FEBRUARY 16, 2022 AND MARCH 7, 2022 Each member of the board of directors (the ?Board?) of Ge |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of (Commission File Number) (IRS Emp |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPOR |
|
| March 10, 2022 |
2018 Inducement Award Plan, as amended February 16, 2022* EXHIBIT 10.14 Geron Corporation 2018 Inducement Award Plan Adopted by the Board of Directors: December 14, 2018 (with 3,000,000 share reserve) Amended and Restated: January 29, 2019 (added 5,000,000 shares) Amended and Restated: February 11, 2020 (added 1,300,000 shares) Amended and Restated: February 1, 2021 (added 800,000 shares) Amended and Restated: May 11, 2021 (added 5,000,000 shares) Amende |
|
| March 10, 2022 |
EXHIBIT 4.1 DESCRIPTION OF CAPITAL STOCK References herein to ?Geron,? ?our,? ?we,? ?us? and the ?Company? refer only to Geron Corporation. General Our restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 675,000,000 shares of common stock, par value $0.001 per share, and 3,000,000 shares of preferred stock, par value $0.001 per share. The followin |
|
| March 10, 2022 |
EXHIBIT 99.1 Press Release Dated March 10, 2022 Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Expected in Early January 2023 FOSTER CITY, Calif., March 10, 2022 - Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase |
|
| February 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 16, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 14, 2022 |
GERN / Geron Corporation / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* GERON CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 374163103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2022 |
GERN / Geron Corporation / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Geron Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 374163103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 10, 2022 |
GERN / Geron Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Geron Corp. Title of Class of Securities: Common Stock CUSIP Number: 374163103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| January 10, 2022 | ||
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of (Commission File Number) (IRS E |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of (Commission File Number) (IRS E |
|
| November 10, 2021 |
EXHIBIT 99.1 Press Release Dated November 9, 2021 Geron Presents Investor Event Highlights Strong Evidence of Disease-Modifying Activity of Imetelstat Provides Compelling Differentiation for Phase 3 Development Programs in Lower Risk MDS and Refractory MF Significant Unmet Needs in Lower Risk MDS and Refractory MF Addressable by Imetelstat Provide Potential Large Market Opportunities New Programs |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERO |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON COR |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 75-2287752 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 919 E. Hillsdale Blvd, Suite 250 Foster City, California 94404 (Add |
|
| August 16, 2021 |
2018 Inducement Award Plan, as amended May 11, 2021* EXHIBIT 10.3 Geron Corporation 2018 Inducement Award Plan Adopted by the Board of Directors: December 14, 2018 (with 3,000,000 share reserve) Amended and Restated: January 29, 2019 (added 5,000,000 shares) Amended and Restated: February 11, 2020 (added 1,300,000 shares) Amended and Restated: February 1, 2021 (added 800,000 shares) Amended and Restated: May 11, 2021 (added 5,000,000 shares) 1.Gener |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of (Commission File Number) (IRS Em |
|
| August 16, 2021 |
EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as |
|
| August 16, 2021 |
EXHIBIT 99.1 Press Release Dated August 16, 2021 Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023 Completion of Enrollment in IMerge Phase 3 Expected in the Fourth Quarter of 2021 Investor Day Planned for November Second Quarter and Year to Date 2021 Financial Results Also Reported Conference Call Scheduled f |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2021 |
2018 Equity Incentive Plan, as amended EXHIBIT 10.1 Geron Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: March 27, 2018 Approved by the Stockholders: May 15, 2018 Amended by the Board of Directors: February 12, 2020 Approved by the Stockholders: June 5, 2020 Amended by the Board of Directors: February 2, 2021 Approved by the Stockholders: May 11, 2021 1. General. (a) Successor to and Continuation of Prior Pla |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2021 |
Certificate of Amendment of the Restated Certificate of Incorporation EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF GERON CORPORATION, a Delaware corporation The undersigned, Stephen N. Rosenfield, hereby certifies that: FIRST. He is the duly elected and acting Executive Vice President, Chief Legal Officer and Corporate Secretary of Geron Corporation, a Delaware corporation (the ?Corporation?). SECOND. The Corporation?s Restate |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CO |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 10, 2021 |
EXHIBIT 99.1 Press Release Dated May 10, 2021 Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights IMerge Phase 3 Clinical Trial in Myelodysplastic Syndromes 75% Enrolled and On Track to Complete Enrollment in Second Half of 2021 Two Abstracts Accepted by European Hematology Association for 2021 Virtual Congress Conference Call Scheduled for 4:30 p.m. ET Today FOSTE |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-20859 GERON CORPORAT |
|
| March 11, 2021 |
2018 Inducement Award Plan, as amended* EXHIBIT 10.20 Geron Corporation 2018 Inducement Award Plan Adopted by the Board of Directors: December 14, 2018 Amended and Restated by the Compensation Committee of the Board of Directors: January 29, 2019; February 11, 2020; and February 1, 2021 1. General. (a) Eligible Award Recipients. Awards may only be granted to Employees who satisfy the standards for inducement grants under Rule 5635(c)(4) |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 11, 2021 |
EXHIBIT 99.1 Press Release Dated March 11, 2021 Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Conference Call Scheduled for 4:30 p.m. ET today FOSTER CITY, Calif., March 11, 2021 — Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematol |
|
| March 11, 2021 |
PRE 14A 1 gern-pre14a20210511.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| February 16, 2021 |
SC 13G/A 1 gern13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Geron Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 374163103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GERON CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 374163103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Geron Corp. Title of Class of Securities: Common Stock CUSIP Number: 374163103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1( |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 1, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 8, 2021 | ||
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2021 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-20859 75-2287752 (State or other jurisdiction of (Commission File Number) (IRS Empl |
|
| November 6, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-248637 PROSPECTUS $100,000,000 Common Stock In accordance with the terms of an at market issuance sales agreement, or the sales agreement, dated as of September 4, 2020, with B. Riley Securities, Inc. or B. Riley Securities, we may offer and sell shares of our common stock from time to time through B. Riley Securities having an aggregate offeri |
|
| November 5, 2020 |
exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2020 and is entered into by |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-20859 75-2287752 (State or other jurisdiction of (Commission File Number) (IRS Emp |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-20859 GERON |
|
| November 5, 2020 |
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events EXHIBIT 99.1 Press Release Dated November 5, 2020 Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events FOSTER CITY, Calif., November 5, 2020 - Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020. The Company will host a conference call today at 4:30 p.m. ET to |
|
| November 4, 2020 |
Geron Corporation 919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404 +1 650 473 7770 main +1 650 473 7750 fax www.geron.com VIA EDGAR November 4, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Abby Adams Re: Geron Corporation Acceleration Request for Registration Statement on Form S-3 File No. 333-248637 Dear |
|
| October 9, 2020 |
Geron Corporation 919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404 +1 650 473 7770 main +1 650 473 7750 fax www.geron.com VIA EDGAR October 9, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Abby Adams Re: Geron Corporation Acceleration Request for Registration Statement on Form S-3 File No. 333-248637 Dear |
|
| October 7, 2020 |
Geron Corporation 919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404 +1 650 473 7770 main +1 650 473 7750 fax www.geron.com VIA EDGAR October 7, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Abby Adams Re: Geron Corporation Acceleration Request for Registration Statement on Form S-3 File No. 333-248637 Dear |
|
| October 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2020 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| September 10, 2020 |
United States securities and exchange commission logo September 10, 2020 Olivia K. |
|
| September 10, 2020 |
United States securities and exchange commission logo September 10, 2020 Olivia K. |
|
| September 4, 2020 |
- REGISTRATION STATEMENT FOR SPECIFIED TRANSACTIONS BY CERTAIN ISSUERS As filed with the Securities and Exchange Commission on September 4, 2020 Registration No. |
|
| September 4, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate EXHIBIT 4.8 GERON CORPORATION AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF GERON CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “ Agreement ”), dated as of [●], between GERON CORPORATION , a Delaware corporation (the “ Company ”) and [●], a [corporation] [national banking association]organized and existing under th |
|
| September 4, 2020 |
Form of Indenture between Geron Corporation and a trustee to be named EXHIBIT 4.5 GERON CORPORATION Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 5 Section 2. |
|
| September 4, 2020 |
Exhibit 10.1 At Market Issuance Sales Agreement, dated September 4, 2020, by and between Geron Corporation and B. Riley Securities, Inc. GERON CORPORATION Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement September 4, 2020 B. Riley Securities, Inc. 299 Park Avenue, 7th Floor New York, NY 10107 Ladies and Gentlemen: Geron Corporation, a Delaware corporation (the “Company” |
|
| September 4, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate EXHIBIT 4.7 GERON CORPORATION AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF GERON CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “ Agreement ”), dated as of [●], between GERON CORPORATION , a Delaware corporation (the “ Company ”) and [●], a [corporation] [national banking association] organized and existing under t |
|
| September 4, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2020 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-20859 75-2287752 (State or other jurisdiction of incorporation) (Commission File |
|
| September 4, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate EXHIBIT 4.6 GERON CORPORATION AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF GERON CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “ Agreement ”), dated as of [●], between GERON CORPORATION , a Delaware corporation (the “ Company ”) and [●], a [corporation] [national banking association] organized and existing under the laws o |
|
| August 6, 2020 |
Quarterly Report - Q2 2020 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-20859 GERON CORPO |
|
| August 6, 2020 |
Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events EXHIBIT 99.1 Press Release Dated August 6, 2020 Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events FOSTER CITY, Calif., August 6, 2020 - Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call today at 4:30 p.m. ET to discus |
